A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes. POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)

JACC: Cardiovascular Interventions

Volumn 2, Issue 6, 2009, Pages 524-531

  Takagi, Tsutomu ^a   Okura, Hiroyuki ^b   Kobayashi, Yoshiki ^c   Kataoka, Toru ^c   Taguchi, Haruyuki ^b   Toda, Iku ^b   Tamita, Koichi ^d   Yamamuro, Atsushi ^d   Sakanoue, Yuji ^e   Ito, Akira ^e   Yanagi, Shiro ^f   Shimeno, Kenji ^f   Waseda, Katsuhisa ^g   Yamasaki, Masao ^g   Fitzgerald, Peter J ^g   Ikeno, Fumiaki ^g   Honda, Yasuhiro ^g   Yoshiyama, Minoru ^c   Yoshikawa, Junichi ^h  

^a Takagi Cardiology Clinic   (Japan)

^b Bell Land General Hospital   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e Osaka City General Medical Center   (Japan)

^f Fuchu Hospital   (Japan)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h Osaka Ekisaikai Hospital   (Japan)

Author keywords

diabetes mellitus; restenosis; stent; ultrasound

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICORANDIL; NITRIC ACID DERIVATIVE; PIOGLITAZONE; SULFONYLUREA; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD GLUCOSE; CALIFORNIA; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART DISEASES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METALS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 66949122528     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.04.007     Document Type: Article

References (49)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
4. Lemos P.A., Hoye A., Goedhart D., et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 109 (2004) 1366-1370
5. Zahn R., Hamm C.W., Schneider S., et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. Am Heart J 152 (2006) 1146-1152
6. Kitoga M., Pasquet A., Preumont V., et al. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. Diabetes Metab 34 (2008) 62-67
7. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32 (1998) 584-589
8. Kornowski R., Mintz G.S., Kent K.M., et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95 (1997) 1366-1369
9. Okura H., Morino Y., Oshima A., et al. Preintervention arterial remodeling affects clinical outcome following stenting: an intravascular ultrasound study. J Am Coll Cardiol 37 (2001) 1031-1035
10. Okura H., Taguchi H., Kubo T., et al. Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study. Heart 93 (2007) 1219-1225
11. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146 (2003) E5
12. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 36 (2000) 1529-1535
13. Takagi T., Yamamuro A., Tamita K., et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89 (2002) 318-322
14. Takagi T., Yamamuro A., Tamita K., Katayama M., and Morioka S. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. J Cardiol 45 (2005) 139-147
15. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
16. Osman A., Otero J., Brizolara A., et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147 (2004) e23
17. Rosmarakis E.S., and Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 154 (2007) 144-150
18. Takagi T., Yoshida K., Akasaka T., et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 36 (2000) 731-738
19. Nishio K., Sakurai M., Kusuyama T., et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 29 (2006) 101-106
20. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
21. Katayama T., Ueba H., Tsuboi K., et al. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 153 (2007) 762.e1-762.e7
22. Goetze S., Xi X.P., Graf K., Fleck E., Hsueh W.A., and Law R.E. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452 (1999) 277-282
23. Shinohara E., Kihara S., Ouchi N., et al. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 136 (1998) 275-279
24. Yasunari K., Kohno M., Kano H., Yokokawa K., Minami M., and Yoshikawa J. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 81 (1997) 953-962
25. Igarashi M., Hirata A., Yamaguchi H., et al. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 50 (2001) 955-962
26. Aizawa Y., Kawabe J., Hasebe N., Takehara N., and Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104 (2001) 455-460
27. Ishibashi M., Egashira K., Hiasa K., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40 (2002) 687-693
28. Kasai T., Miyauchi K., Yokoyama T., et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 197 (2008) 612-619
29. Joner M., Farb A., Cheng Q., et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27 (2007) 182-189
30. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
31. Bodary P.F., Vargas F.B., King S.A., Jongeward K.L., Wickenheiser K.J., and Eitzman D.T. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 3 (2005) 2149-2153
32. Kanehara H., Tohda G., Oida K., Suzuki J., Ishii H., and Miyamori I. Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. Thromb Res 108 (2002) 227-234
33. Li D., Chen K., Sinha N., et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65 (2005) 907-912
34. Komatsu R., Ueda M., Naruko T., Kojima A., and Becker A.E. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 98 (1998) 224-233
35. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
36. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., and Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (2007) 1772-1780
37. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
38. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
39. de la Torre-Hernandez J.M., Alfonso F., Hernandez F., et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51 (2008) 986-990
40. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 50 (2007) 501-508
41. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
42. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
43. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
44. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007) 813-818
45. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
46. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
47. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
48. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
49. Erdmann E., Charbonnel B., Wilcox R.G., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30 (2007) 2773-2778